Strategies for Reducing Polypharmacy and Other Medication-Related Problems in Chronic Kidney Disease
Strategies for Reducing Polypharmacy and Other Medication-Related Problems in Chronic Kidney Disease
复制标题
DOI：
10.1111/j.1525-139x.2009.00629.x
复制
发表时间：
2010-01-01
影响因子：
1.6
通讯作者：
Bakus, Jodie L.
中科院分区：
文献类型：
--
作者：
Mason, Nancy A.;Bakus, Jodie L.
药物相关问题在慢性肾脏病 (CKD) 患者中非常常见。这些问题通常是可以避免的，但可能会给患者带来不利的后果和高昂的财务成本。尽管存在这些风险，但在医学上通常有必要开出多种药物来治疗 CKD 的合并症。此外，患者使用非处方药以及药代动力学和药效学参数的变化可能进一步导致 CKD 中的药物相关问题，包括药物相互作用和剂量调整的需要。结构化药物评估流程是降低与药物相关问题相关的风险的一种方法。这个多方面的过程包括全面的用药史访谈、结构化治疗评估以及医疗团队成员之间的公开沟通。提供了此过程的详细描述，以帮助医疗保健提供者解决这一重要问题。
Medication-related problems are very common in patients with chronic kidney disease (CKD). These problems are often avoidable and can result in detrimental patient consequences and high financial costs. Despite these risks, it is often medically necessary to prescribe multiple medications to treat the comorbid conditions that accompany CKD. In addition, patients' use of nonprescription medications and changes in pharmacokinetic and pharmacodynamic parameters may further contribute to medication-related problems in CKD, including drug interactions and the need for dosage adjustments. A structured medication assessment process is one approach to reducing the risks associated with medication-related problems. This multifaceted process involves a comprehensive medication history interview, structured therapy assessment, and open communication between members of the medical team. A detailed description of this process is provided to aid healthcare providers in addressing this important issue.